STATCenter·
STAT+: Breast cancer pill from AstraZeneca misses mark in pivotal trial
A pill from AstraZeneca failed to improve outcomes in closely watched breast cancer study, a result that could limit the use of the medicine.
Read at STAT →
Health · 1 sources covering this
STAT+: Breast cancer pill from AstraZeneca misses mark in pivotal trial
A pill from AstraZeneca failed to improve outcomes in closely watched breast cancer study, a result that could limit the use of the medicine.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/79f4c68e536d7c48e652b53fe6d74e3b7de35bc0" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: Breast cancer pill from AstraZeneca misses mark in pivotal trial"></iframe>
